Deregulation of cyclin E expression and/or high levels have been reported in a variety of tumors and have been used as indicators of poor prognosis. Although the role that cyclin E plays in tumorigenesis remains unclear, there is evidence that it confers genomic instability when deregulated in cultured cells. Here we show that deregulated expression of a hyperstable allele of cyclin E in mice heterozygous for p53 synergistically increases mammary tumorigenesis more than that in mice carrying either of these markers individually. Most tumors and tumor-derived cell lines demonstrated loss of p53 heterozygosity. Furthermore, this tumor susceptibility is related to the number of times the transgene is induced indicating that it is directly attributable to the expression of the cyclin E transgene. An indirect assay indicates that loss of p53 function is an early event occurring in the mammary epithelia of midlactation mammary glands in which cyclin E is deregulated long before evidence of malignancy. These data support the hypothesis that deregulated expression of cyclin E stimulates p53 loss of heterozygosity by promoting genomic instability and provides specific evidence for this in vivo. Cyclin E deregulation and p53 loss are characteristics often observed in human breast carcinoma.
Introduction
Loss of normal cell cycle control is well-established as a key event in tumorigenesis, particularly deregulation of commitment to divide and of the G1/S-phase transition (Malumbres and Barbacid, 2001; Blagosklonny and Pardee, 2002) . Entry into S-phase of the cell cycle is dependent upon kinase activity controlled by the G1 cyclins D and E and possibly cyclin A. These act through independent kinase partners and phosphorylate discrete subsets of the cell cycle machinery as well as common targets such as the retinoblastoma protein.
Mutations resulting in aberrant expression of both cyclin D and E have been implicated as putative tumorigenic events and are used as prognostic indicators in a variety of tissue tumors (Malumbres and Barbacid, 2001) . Cyclin D expression appears to be responsive to mitogenic stimuli and therefore gain-of-function mutations, including gene amplification, may represent a bypass of various receptor/ligand-dependent mitogenic stimuli. Cyclin E functions downstream of cyclin D and appears to contribute to entry into S-phase both through the hyperphosphorylation of Rb and by Rb-independent mechanisms (Lukas et al., 1997; Seghezzi et al., 1998; Geisen and Moroy, 2002; Wei et al., 2003) .
Upregulation of cyclin D and/or E is thought to be a common feature of many malignancies. However, whether this phenomenon is a simple marker of the disease state or whether aberrant cyclin D and/or E expression acts as a mediator of malignancy is under debate. Cyclin E gene amplification is infrequent, whereas cyclin D gene amplifications are often found in tumors (Barnes and Gillett, 1998; Malumbres and Barbacid, 2001; Bieche et al., 2002) . Alteration of cyclin E in tumors can correspond to elevated expression of normally regulated protein or deregulated expression where the protein is expressed throughout the cell cycle rather than transiently at the G1/S-phase boundary. Such deregulation correlates with accelerated entry into S-phase and prolongs S-phase without shortening the total cell cycle period (Resnitzky et al., 1994; Ohtsubo et al., 1995) . Moreover, there is evidence emerging to support S-phase defects when cyclin E is expressed inappropriately during the cell cycle (Ekholm-Reed et al., 2004a) . Therefore, it may be temporal deregulation of cyclin E rather than simple overexpression per se that contributes to cell cycle perturbation. Indeed, at least two lines of research support a role for deregulated cyclin E expression in tumorigenesis. In culture, deregulated expression of cyclin E causes a low level of chromosomal segregation errors leading to genomic instability and aneuploidy (Spruck et al., 1999) , a phenomenon not observed if cyclin A or cyclin D are expressed under identical conditions but is increased with the hyperstable cyclin E T380A allele. Chromosomal instability and aneuploidy are thought to be mediators of tumorigenesis. Furthermore, a murine transgenic model expressing cyclin E in the mammary epithelium leads to hyperplasia and mammary tumors (Bortner and Rosenberg, 1997) , albeit at a low frequency. In both instances the expression of cyclin E was deregulated with respect to the cell cycle.
Normally, cyclin E accumulation is regulated by periodic transcription and cell cycle-dependent protein turnover. Cyclin E/Cdk2 activity is transient at the G1-S phase transition, first de-repressed by sequestration or destruction of inhibitory factors such as p27 Kip1 and subsequently eliminated by phosphorylation of cyclin E, targeting it for ubiquitin-dependent degradation by the 26S proteasome (Clurman et al., 1996; Won and Reed, 1996; Strohmaier et al., 2001; Welcker et al., 2003) . Mutation of a critical phosphorylation site required for cyclin E ubiquitylation from a threonine to an alanine (e.g. T380A) confers hyperstability (Clurman et al., 1996; Won and Reed, 1996) , although to our knowledge mutations of cyclin E inducing stability have not been reported in tumors. More recently, the SCF specificity factor that targets phosphorylated cyclin E for ubiquitylation (hCdc4/Fbw7/Ago) and subsequent degradation was identified with significant mutation rates in primary neoplasms of the endometrium, ovary, colon and breast (Moberg et al., 2001; Strohmaier et al., 2001; Spruck et al., 2002; Rajagopalan et al., 2004) . Consistent with a role for deregulation of cyclin E in tumorigenesis, mutations in hCdc4/Fbw7 result in deregulation of cyclin E expression throughout the cell cycle (Ekholm-Reed et al., 2004b) and accumulation of the phosphorylated form (Moberg et al., 2001; Strohmaier et al., 2001; Spruck et al., 2002) . Hence there are several biologically relevant reasons to suspect deregulation of cyclin E rather than overexpression per se to represent a genotoxic insult. Although these studies suggest that hCdc4 may act as a tumor suppressor, it remains to be demonstrated that the associated deregulation of cyclin E would cause tumorigenesis via a mechanism of chromosomal instability in vivo.
We hypothesized that by crossing mice transgenic for the wild-type or the hyperstable allele of human cyclin E to mice heterozygous at a tumor suppressor locus, tumorigenesis would be enhanced synergistically through increased loss of the remaining wild-type allele. We expected this to be manifest in both increased penetrance and decreased latency of tumorigenesis as only one tumor suppressor allele was required to be lost. Furthermore, we expected that the hyperstable form of cyclin E would have a more dramatic effect. One of the best-characterized tumor suppressor genes is Trp53 encoding p53. In mice, nullizygosity at the Trp53 locus on chromosome 11 results in early adult mortality at 6 months mainly from lymphomas (Donehower et al., 1992; Jacks et al., 1994) . However, heterozygosity confers tumor susceptibility without severe restriction on life expectancy; approximately 1.5 years for p53 þ /À mice. We therefore generated mice that were heterozygous at the p53 locus and transgenic for either the wild-type or hyperstable allele (Won and Reed, 1996) of human cyclin E targeted to the mammary gland. We further anticipated that any effect on mammary tumorigenesis would be manifest without significantly affecting the non-mammary tumor spectrum or incidence observed in the non-transgenic mice but heterozygous at the Trp53 locus.
We show here that p53 heterozygosity and the hyperstable cyclin E T380A allele of human cyclin E act synergistically to induce mammary tumorigenesis in a murine model without concomitantly altering the nonmammary tumor spectrum or incidence. Furthermore, we provide evidence that loss of p53 function is increased in preneoplastic mammary epithelia in which cyclin E is deregulated.
Results
Cyclin E transgenic mice, transgene zygosity and expression Both the cyclin E and hyperstable cyclin E-T380A alleles (hereafter T380A) are single-locus insertions inherited independently of the p53 locus located on mouse chromosome 11 and are not sex linked. Genotype did not alter the age of sexual maturity or litter size. All the mouse lines reported here were either homozygous or nullizygous at the transgene locus and wild-type or heterozygous at the p53 locus. These were designated as wild-type, CycE, T380A, p53
þ /À CycE and p53 þ /À T380A. Expression of the transgenes was detected in the nuclei of the mammary epithelia by immunohistochemistry but not in any other tissues examined (all thoracic and abdominal viscera, central and peripheral nervous tissue, hematopoietic tissue, skeletomusculature and integumentary; data not shown). However, trace expression levels of the T380A allele were detectable in the lung and liver upon long immunoblot exposures (>1000 fold less expression than midlactation mammary gland by titration on immunoblots; data not shown).
We have previously shown that a cyclin E transgene in mice is associated with hyperplasia in the mammary gland epithelia concomitant with its expression under the prolactin-responsive b-lactoglobulin promoter (BLG). This phenomenon is transient, occurring in the epithelia during the lactogenic cycle, initially manifest in the final third of pregnancy and persisting until the litter is weaned at 4 weeks post partum. At this point, the mammary epithelia undergo involution and the hyperplastic epithelia are included in this process (Bortner and Rosenberg, 1997) . By standard hematoxylin and eosin staining, hyperplasia in the epithelia of midlactation (2 weeks post partum) mice appeared generally more widespread in T380A transgenic mice than those with the CycE transgene, but no more severe. In the midlactation mammary gland, the T380A transgene was highly expressed with lower expression of the CycE transgene ( Figure 1a) . Titration of the T380A signal against that from CycE mice showed approximately 10-fold higher expression (Figure 1b) . Concomitant with expression in the mammary gland, transgene-associated (human Cyclin E) kinase activity was robustly elevated in mice with the T380A allele (Figure 1c) . However, kinase levels associated with the CycE allele were not significantly elevated above the intrinsic background of the assay.
The tumor spectrum in p53
þ /À mice is unaffected by the cyclin E transgenes The spectrum of tumors seen in p53 þ /À mice is wellestablished. We observed a tumor spectrum similar to those of published reports (Donehower et al., 1992; Jacks et al., 1994) . In multiparous p53
þ /À mice we observed a moderate rate of mammary carcinoma, 7% (3/45). The tumor spectrum in p53 þ /À mice with either T380A or CycE transgene was similar (Table 1) with the exception of a small frequency of bronchiolar/alveolar lesions in the lungs of mice bearing the T380A transgene. However, these incidental findings were small (o3 mm) single lesions observed during necropsy at 18 months. Representative sections from non-mammary tumors (including the lung lesions) were consistently negative for transgene expression but positive for endogenous mouse cyclin E (data not shown). These findings demonstrate that expression of cyclin E under control of the BLG promoter does not significantly promote non-mammary tumor formation. p53 heterozygosity acts synergistically with the T380A allele to promote mammary tumorigenesis and decrease life expectancy The p53 þ /À T380A mice showed a slight, but significant, reduction in life expectancy when compared to p53 þ /À mice (Figure 2a ; Po0.005, log-rank test). Although approximately 25% of p53 þ /À and 70% of T380A mice were tumor-free at 1.5 years, no p53 þ /À T380A animal reached this age tumor-free (Table 1) . Some reduction in life expectancy was anticipated due to the increased numbers of mammary tumors; indeed when analysis of survival was restricted to only mice without mammary tumors, the survival was comparable (P ¼ 0.212; logrank test; data not shown). Titration of T380A transgene expression against that in the cyclin E mice demonstrates that the steady state expression is approximately 10-fold higher in the T380A mice. (c) Cyclin E-dependent kinase activity is higher in T380A mice. Extracts from 2-week midlactation mammary glands were immunoprecipitated with HE172 human cyclin E-specific IgG. Histone H1 phosphorylation in the presence of radiolabeled ATP was greater in T380A mice than wildtype mice (without the human cyclin E transgene), whereas in the cyclin E mice transgene-dependent kinase activity was not elevated above background. Kinase activity in p53 þ /À T380A mice was comparable to that in the T380A mice. Àve and þ ve controls represent no protein added and recombinant CyclinE/Cdk2 extract from SF9 cells, respectively. Even though the tumor spectrum was unaltered in p53 þ /À mice, with or without cyclin E transgenes, the frequency with which mammary tumors were observed was markedly changed in the presence of the hyperstable cyclin E transgene. In p53 þ /À mice without a transgene, mammary tumorigenesis was observed in 7% (3/45). In p53 þ /À mice with the wild-type cyclin E transgene, tumor penetrance was unaltered at 6% (2/32) whereas in mice bearing the hyperstable T380A allele, the penetrance was increased to 54% (30/56) (Figure 2b ). This increase in tumor penetrance was synergistic as it was significantly greater than the addition of the frequencies observed in the control lines (Po0.001; Fisher's exact test and w 2 -test). The synergistic effect was even greater if we consider that three of the p53 þ /À T380A mice developed two independent mammary tumors giving a normalized ratio of 7:12:59 (p53 þ /À :T380A:p53 þ /À T380A). The mammary tumor frequency in the mice transgenic for the hyperstable allele in the absence of a p53 mutation was merely 12% (4/34). Mammary tumor latency was mildly decreased in p53 þ /À T380A mice but did not reach significance (ANOVA; Po0.28; Figure 2c ), possibly due to the small number of tumors in mice of other genotypes.
All mammary tumors were intermediate to high-grade carcinomas (Figure 3 ) with high mitotic rates, considerable nuclear atypia, poor acinar differentiation and areas of necrosis. Local invasion of the skin and/or musculature was usually observed. However, despite the overt malignant biological behavior, hematogenous metastases were not observed by routine histological examination of lung, liver and marrow. Lymphatic dissemination was noted in several cases but was a generally infrequent observation. More tumors arose in the cervical mammary glands than were expected given that the cervical mammary glands constitute only 2 of the 10 mammary glands in the mouse. These cervical mammary tumors were also associated with a smaller average litter size (data not shown). Many of the nonmammary malignant neoplasms exhibited both haematogenous and lymphatic metastatic spread in addition to local invasion.
Mammary tumors, especially in p53 þ /À T380A mice, were aggressive fast-growing lesions. Typically a size of 1 cm was reached within 2-8 days of the lesion being first detected. Furthermore, several of p53 þ /À T380A lesions exhibited extraordinarily high mitotic indices, 20-30 mitotic figures per Â 40 objective field, with frequent areas of necrosis. By contrast, lesions of T380A or p53 þ / À mice were typified by more moderate mitotic rates of 4-20 figures per Â 40 objective field (Table 2) . Although several mice were found to have multiple primary lesions in different tissues, multiple mammary lesions only developed in p53 þ /À T380A mice (3/56; each mouse, however, was counted as a single data point for penetrance analysis). In the few F1 generation p53 T380A mice, where each mouse is heterozygous at the locus of transgene insertion, mammary tumorigenesis was observed at an equivalent rate of 60% (3/5) indicating that hemizygosity at the transgene locus may be sufficient for full penetrance.
Histologically, most of the mammary tumors were composed of dense sheets or nests of neoplastic cells, usually interspersed with a fine stromal component Includes three mice with two independent mammary tumors.
e Loss of both wild-type alleles rather than heterozygosity per se.
squamous carcinomas (1 p53 þ /À and 1 T380A) were classified as intermediate grade. All of the remaining lesions were classified as high grade. Two instances of carcinoma in situ (both high grade) were observed in p53 þ /À T380A mice at necropsy. These were not observed in the other genotypes.
Only four p53 þ /À T380A mice had to be killed before the age at which the first mammary tumor was noted. However, these mice offered an opportunity to look for preneoplastic mammary lesions in the period between the last pregnancy and the relatively long latency before palpable tumor formation. Of these four mice, two developed thymic lymphoma at ages 6.8 and 9.8 months, one developed an osteosarcoma, and the fourth was killed due to severe dermatitis. Immunohistochemistry revealed the presence of a few human cyclin E immunoreactive cells located ablumenal to the ducts of all four mice (see below). In one of the mice with lymphoma, a focus of alveolar hyperplasia was noted in which the epithelia stained positive for expression of the T380A transgene (Figure 3c ).
Representing tumor incidence in mice susceptible to neoplastic lesions in multiple organ systems can be problematic in ensuring that the appropriate conclusions are drawn. It is important therefore to clarify two observations that do not bear significantly on our findings. Firstly, the incidence of osteosarcoma in the p53 þ /À T380A mice appears decreased compared to the other p53 þ /À bearing genotypes (Table 1) . This is a result of the earlier presentation of mammary lesions and thus represents underscoring of the osteosarcoma incidence due to the longer latency of these lesions. Secondly, in a similar fashion the survival curves indicate that the p53 þ /À T380A mice had a significantly decreased life expectancy compared to the p53 þ /À mice not bearing a transgene. However, while this is almost entirely due to the increased incidence of a neoplastic mammary lesions, the similar survival curve of the p53 þ /À CycE mice was due almost entirely to non-mammary neoplasms and failed to reach significance in comparison to the p53 þ /À genotype.
Mammary tumors show frequent loss of p53 heterozygosity and constitutive expression of the cyclin E transgene In contrast to some reports of the retention of the wildtype allele in 50% of tumors arising in p53 þ /À mice under 18 months of age (Venkatachalam et al., 1998) , we assessed p53 LOH as a more frequent event. The loss of p53 heterozygosity was determined in tumor extracts by Southern analysis (Figure 4 ) and a suite of multiplex PCR reactions. Unequivocal p53 LOH (>50% exon IV signal decrease; see Experimental Procedures) was observed in 100% (3/3) of the p53 þ /À mice, 100% (2/2) p53 þ /À CycE mice and 93% (26/28) of p53 þ /À T380A mice (Table 2) . Of the four T380A mice that developed mammary tumors both wild-type p53 alleles were undetectable in two cases (50%; 2/4) as determined by Southern analysis. There was equivocal loss in one further case (approximately 50% which probably represents loss of one allele) but the fourth case had unequivocal retention of p53 by Southern blot. Indeed, in this later case the wild-type allele was apparently retained even after serial passage of cells cultured from the tumor (Figure 4b ). However, exposure to 5 Gy ionizing radiation, which robustly induced p21 expression in 10T 1/2 cells failed to induce p21 expression in these cells (data not shown), suggesting that p53 is functionally inactivated by some other mechanism than genomic loss of the TRP53 locus. The wild-type p53 allele was invariably absent in cells derived from mammary lesions in p53 heterozygote mice. In tumors retaining the wild-type p53 allele, we cannot rule out p53 inactivation or gain of function by small genetic lesions, such as point mutations, although these data suggest that functional inactivation in the vast majority of the mammary lesions was through loss of a significant chromosomal region or an entire chromosome.
We had previously observed elevated expression of the wild-type human cyclin E transgene in tumors arising in founder transgenic mice (Bortner and Rosenberg, 1997) . We therefore analysed mammary tumors for transgene expression by immunohistochemistry and by immunoblot analysis. Most of the tumors derived from transgenic lines were positive for transgene expression (Table 2 and Figure 3 ). This was somewhat unexpected as these mice were neither pregnant nor lactating. Grading of immunohistochemical staining (Figure 3g ) correlated well with the more quantitative immunoblot analysis. In the vast majority of tumors arising in lines bearing the T380A allele, greater than 50% of the tumor epithelial component was human cyclin E immunoreactive (graded þ þ ). In the tumors where between 10 and 50% of the epithelial component tested positive (graded þ ), a variety of staining patterns were observed although immunoreactivity was low or absent in cells showing squamous metaplasia, in mitosis or adjacent to areas of necrosis. Tumors for which a morphological diagnosis of squamous carcinoma was assigned tested negative.
The incidence of mammary tumors is related to parity in cyclin E transgenic mice Further evidence linking cyclin E deregulation and tumorigenesis is seen in the relationship between tumor penetrance and the number of pregnancies each female underwent (and hence bursts of transgene induction). Although efforts were made to limit each female to two pregnancies, a third pregnancy resulting from copulation during the post-partum estrus was relatively commonplace. Consequently, several mice of each genotype actually had three litters and in two cases four litters. We were able to combine these data with tumorigenesis rates in the few females excluded from the original analysis as they had only a single litter to investigate a putative relationship between parity and tumor penetrance. We anticipated that if during each pregnancy new genetic lesions would be induced in cells that were able to persist through involution these may lead to a correlation between the number of litters and tumor incidence. As this analysis was not a primary study goal, a statistically rigorous analysis of the relatively small numbers of mice with one pregnancy and the relatively small number of categories was not possible. However, there was a trend between parity and mammary tumor penetrance in each of the three transgenic genotypes that went on to develop mammary tumors with the highest incidence observed in the group of mice that had had the greatest number of pregnancies ( Figure 5 ). Furthermore, this trend was not observed in the p53 þ /À mice without a transgene. Although parity appears to reduce the risk of mammary carcinoma in the p53 þ /À mice without the transgene, in agreement with expectations from studies in rodents and humans (Moon, 1969; Swanson et al., 1995; Thordarson et al., 1995; Hamilton and Mack, 2003) , this protection was negated in T380A mice and dramatically reversed in p53 þ /À T380A mice.
Transgene positive-mammary epithelial cells persist through involution Immunohistochemical analysis of tumors had revealed that some uninvolved mammary epithelia were immunopositive for human cyclin E suggesting that either the transgene was being activated late in life, possibly through hormonal influence in reproductive senescence, or that persistent expression of the transgene occurs in cells surviving post-lactation involution. To test this hypothesis we examined transgene expression by immunohistochemistry in 6-week (2 weeks post lactation) and 8-week post-partum mice (by which time involution is complete) and in the mammary epithelia of mice killed prematurely due to early non-mammary neoplasms or non-neoplastic causes. During the involution process at 6 weeks post partum, numerous positive alveoli were still present although a subpopulation of ablumenal immunoreactive cells was seen in some ducts (Figure 6a ). By 8 weeks post partum, involution was complete as determined by histology and whole-mount analysis. However, a few epithelial cells were still immunoreactive and a subpopulation of ablumenal immunoreactive cells was observed even in the smaller ducts (Figure 6c ). This subpopulation was evident in all postlactational T380A-bearing mice and indicates that some cells in which genetic lesions may have occurred persist through involution. The ablumenal location of these cells suggests that they might represent a multipotent epithelial progenitor cell type (basal cells) although, from preliminary analysis (data not shown), they do not appear to represent the stem cell antigen (SCA-1)-positive side population (Welm et al., 2002) . Furthermore, the ablumenal side population stains positive for the cyclin E transgene even in aged virgin mice. The mammary glands of aged virgin transgenic mice also contain some positive staining luminal epithelial cells although fewer than in parous mice. Therefore, it appears likely that the ovine BLG promoter used in these studies, and those of others, may lack elements required to repress BLG expression in mouse mammary epithelial progenitor cells.
Early loss of p53 is increased in mice with the T380A allele As the latency of mammary tumorigenesis was still great and to discriminate between early and late p53 LOH, we determined the rate of p53 inactivation in the midlactation mammary glands of primiparous wild-tpye, p53, T380A and p53 T380A mice by an indirect readout of cyclin B1 deregulation. This approach was adopted, as direct determination of p53 LOH by in situ hybridization for p53 mRNA or immunohistochemistry were problematic for a number of reasons. Firstly, direct measurement of p53 by immunohistochemistry is technically challenging as expression levels are normally extremely low. Secondly, determination of TRP53 locus LOH would require a statistical approach whereby an event expected to be extremely infrequent would be masked by a background of false-negative cells. Furthermore, targeting a relatively small region of DNA deleted in the mutant (approximately 350 bp) within the background of signal noise from the mutant copy would be difficult. Finally, direct measurement of mRNA in situ would require detection of a 106 bp fragment of exon 5 deleted in the mutant strain, but also would be confounded by the existence of a processed pseudogene. Both immunohistochemistry and in situ hybridization of p53 mRNA were attempted without success. It has been established in human tumors that deregulation of cyclin B1 is correlated, at least acutely, with negative p53 status (Innocente et al., 1999; Cui and Donehower, 2000; Krause et al., 2000; Park et al., 2000; Yin et al., 2001; Yu et al., 2002) . In these tumors cyclin B1 is both deregulated with respect to the cell cycle and is massively overexpressed, even to the point where misfolded protein is processed and presented at the cell surface to invoke an immune response (Covini et al., 1997; Yu et al., 2002) . Accordingly, adding functional p53 restores proper cyclin B1 regulation (Yu et al., 2002) . We performed the complementary experiment to partially ablate p53 function in wild-type mouse embryonic fibroblasts by retroviral expression of human papillomavirus E6 (Figure 7c ). After 3-days growth with repeated daily infection, western analysis demonstrated increased levels of cyclin B1 in the E6-infected cells when compared to those infected with the empty vector. Cyclin A levels were comparable between the cultures indicating that this was not due to significant perturbation of the cell cycle. Furthermore, immunofluorescence microscopy demonstrated that this was the case throughout the cell cycle (Figure 7d ). Thus even with only partial knockdown of p53 function typical of HPV E6 expression, there is a significant deregulation of cyclin B1 expression. Analysis of midlactation mammary glands by cyclin B1 immunohistochemistry revealed occasional intensely staining cells individually or in clusters (Figure 7a ). This staining is distinct from cyclin B1 immunopositivity associated with cell proliferation, as similar analysis of rapidly proliferating tissues by the same technique revealed much lower staining intensities (data not shown). Staining in the tumors of the present study showed little or no expression except in occasional isolated foci of cells with low staining intensities in comparison to the midlactation studies. We interpret this as a transient and acute phenomenon that may be selected against þ /À mice that lack a cyclin E transgene.
with further tumor growth as cyclin B1 may act as a tumor antigen (Yu et al., 2002) .
Assessing p53 loss of function by cyclin B1 immunopositivity in midlactation mammary glands provided a number of important mechanistic insights. First, the frequencies of cyclin B1 immunopositive (presumably p53 null) cells associated with the different genotypes mirrored to a striking extent the relative frequencies of mammary tumorigenesis (compare Figure 7b to 2b) . The frequency of strongly cyclin B1 immunopositive cells in the p53
þ /À T380A mammary glands vastly exceeded combined frequency associated with the p53 þ /À and T380A glands. These data suggest, therefore, that the number of p53 null cells generated underlies the probability of developing a mammary tumor. These data are consistent with deregulation of cyclin E driving LOH. Of course, a caveat inherent in these interpretations is that the assumption that cyclin B1 immunoreactivity is always equivalent to p53 nullizygosity cannot be proven. However, the remarkable parallel between cyclin B1 immunoreactivity and mammary tumor frequency strongly supports the validity of this assumption. T380A mouse killed at 9.8 months with a lymphoma. Original magnification for each panel is given in the bottom right corner.
Discussion
The putative role of cyclin E as an oncogene has been based primarily upon immunohistochemical evidence in archival tissue specimens and upon relatively few experimental studies of which most are performed in culture. The in vivo oncogenic potential of cyclin E has been demonstrated in another target organ, the thymocyte, although only in the presence of genotoxic agents (Karsunky et al., 1999) or in p27
-deficient mice (Geisen et al., 2003) . Here we demonstrate a synergistic effect of p53 heterozygosity and transgenic cyclin E expression in the formation of mammary tumors in vivo consistent with a hypothesis initially drawn from tissue culture studies (Spruck et al., 1999) .
Together, the data from this study confirm the oncogenic potential of cyclin E in vivo not only through synergy with the known tumor suppressor, p53, but also through a relationship with parity linked with the expression of the hyperstable transgene in our model. With our original hypothesis, deregulated cyclin E would be sufficient to induce genomic instability and that this would induce loss of a single tumor suppressor allele. The frequent p53 LOH we report supports this hypothesis with the vast majority of the tumors showing unequivocal LOH. The few cases where the allele was detectable but at a level significantly less than 50% of the mutant allele, could be explained by the relatively high stromal component in these lesions or may represent functional inactivation through genomic alterations not amenable to analysis by Southern blotting, but could still represent retention in a small fraction of a putative heterozygous neoplastic epithelial component. In such cases p53 LOH may have occurred later in tumor development. Regardless, the high percentage of tumors exhibiting unequivocal p53 LOH in the p53 þ /À T380A mice is strongly suggestive of a mechanism involving cyclin E-mediated genomic or chromosome instability.
Until recently there was little evidence to link p53 status with cyclin E deregulation in tumorigenesis but timely reports may have relevance to the present study. Under its own promoter, a hyperstable cyclin E 'knockin' allele failed to induce significant predilection to proliferative lesions (Loeb et al., 2005) . However, this allele significantly reduced the latency of tumors arising in a p53 null background. Our study targeted hyperstable cyclin E to a specific tissue which differs from this model in that our mice carried a single wild-type p53 allele. We found loss of the remaining allele in most (if not all) tumors arising in these mice. This observation raises the question of whether loss of the remaining allele is an early event in tumorigenesis. Our observation of cyclin E-associated cyclin B1 deregulation (as an indirect means of assessing p53 loss of function in midlactation mammary glands) strongly suggests that this is indeed an extremely early event in these lesions setting the stage for the tumorigenic process. However, loss of the remaining p53 allele might also act synergistically to promote tumorigenesis through elevated kinase activity potentiated by abrogation of the p53/p21 pathway (Loeb et al., 2005) . This may be mediated by centrosome hyperamplification (Mussman et al., 2000; Kawamura et al., 2004) , perturbation of rereplication complex assembly (Ekholm-Reed et al., 2004a) or by other mechanisms related to genome/ replicative stress (Bartkova et al., 2005; Gorgoulis et al., 2005) . Therefore, both the ultimate penetrance and the aggressiveness of the tumors observed in the T380A/ p53-heterozygous background may reflect both enhanced p53 LOH, and then subsequently a heightened sensitivity to other cyclin E-mediated oncogenic events, in effect a positive feedback loop.
Several studies suggest that p53 may be haploinsufficient as a tumor suppressor in mice with the wild-type allele frequently retained in tumors cells (Venkatachalam et al., 1998) . This may explain why the effect of deregulated cyclin E is higher in p53 þ /À than in p53
þ / þ mice and suggests that p53 LOH may occur after initial cyclin E-mediated genetic lesions. Although our data cannot absolutely exclude this explanation, they argue against it. The high frequency of p53 inactivation in our study together with that seen with other examples of mammary tumorigenic synergy -for example, p53 (Jonkers et al., 2001) and in a p53
conditional Rb-inactivated mouse (Simin et al., 2004) support the notion that inactivation of p53, rather than haploinsufficiency, is a key event in mammary tumorigenesis in mice although a systematic study in spontaneous mammary lesions of mice is needed. This is supported by work on human breast cancers reporting that overexpression of cyclin E is associated with specific mutation types in p53 (Lindahl et al., 2004) . It seems likely, therefore, that the increased tumorigenesis in our mice may be accounted for by increased p53 LOH (or loss of function) induced by cyclin E deregulation, and is consistent with our original hypothesis that deregulated cyclin E induces tumorigenesis through genomic instability. Our initial expectations were that cyclin E deregulation would increase tumorigenesis through accelerated tumor suppressor LOH, manifest in both increased tumor penetrance and decreased latency. Although this is partially true in the case of p53 þ /À T380A, where LOH and penetrance were dramatically increased, the apparent trend to decreased latency was not statistically significant, probably due to the small number of tumors associated with the other genotypes. The most likely explanation is that some cells persist through involution with genetic lesions but, in the absence of growth stimuli, require a long latency before malignant transformation is complete. Possibly, time-dependent genetic changes are also required in the supporting stroma (Kurose et al., 2002) . The persistence of these immunoreactive cells at 8 weeks post lactation (when involution is complete), the relationship between tumor penetrance and parity, and the detection of at least one presumed preneoplastic lesion in a mouse post-involution strongly support this explanation. Indeed, long latency intervals are observed in other mammary carcinogen models, also consistent with multiple timedependent events downstream of a primary genetic lesion (see below). It is probable that a decrease in latency would become evident in this cohort were it possible to extend the study temporally without agerelated non-mammary neoplasms complicating the analysis.
Surprisingly, none of the CycE mice in the present study developed overt neoplastic lesions whereas in a C3H Â C57BL/6J background we had observed that approximately 10% developed mammary carcinomas (Bortner and Rosenberg, 1997) . Furthermore, in our T380A transgenic mice only a relatively small percentage of the multiparous females, 12%, proceeded to develop mammary tumors as opposed to 25% in the original C3H Â C57BL/6J (F0) genetic background (data not shown). These results may be due to the greater representation of the C57BL/6J genetic background in the mice of the present study (which are generally less susceptible to mammary tumors than mice in the C3 H background). This difference in tumor incidence also reflects the midlactation protein levels and kinase activity between the CycE and T380A genotypes, which results from hyperstability of the T380A allele. Indeed, we believe it is the deregulation of cyclin E expression with respect to the cell cycle that leads to lengthening of the cell cycle and perturbation of pre-replication complex formation as we have previously described (Resnitzky et al., 1994; EkholmReed et al., 2004a) .
The relationship between parity and tumor penetrance is strongly supportive for a causative role of the cyclin E transgene tumorigenesis. Parity is known to modulate the risk of mammary tumorigenesis in both humans and rodents (Moon, 1969; Thordarson et al., 1995; Hamilton and Mack, 2003) . In mice, it has been demonstrated that parity protects against mammary carcinogenic insult and that the effects of the carcinogen are dependent upon the mitogenic environment at the time of insult; the beneficial effect of parity is reversed by prolactin stimulation from pituitary isografts. In our model, the putative genotoxic insult (induction of the cyclin E transgene) is at the time of maximal mitogenic stimulus for the mammary epithelium, possibly reversing the protective effect of pregnancy and lactation. Significantly, while a refractoriness to mammary tumorigenesis is apparent with parity in p53 þ /À mice, and less so in T380A mice, the number of pregnancies in p53 þ /À T380A mice appears to increase the risk of tumor formation rather than decrease the risk. This observation suggests that genetic lesions are induced during pregnancy/lactation, through activation of the transgene, and that at least some cells persist through postlactational involution neutralizing the protective effects of parity.
In a parallel arm of the study we examined the possible role of another tumor suppressor protein, RB. Like p53 þ /À mice, the tumor susceptibility in Rb þ /À mice is well-characterized (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992) . In a parallel study we examined the effects of CycE and T380A in Rb þ /À mice in an identical manner to that described for p53 þ /À mice. Both the CycE and T380A transgenes were inherited independently of the Rb locus on chromosome 14. However, unlike p53, Rb heterozygosity restricts the life span of mice to 9-13 months due to the high penetrance of pituitary and thyroid lesions. The tumor spectrum we observed was similar in Rb
T380A mice, and comparable to that of the literature. However, no mammary tumors were observed in any of the three genotypes. Given the long latency, even in our p53 þ /À cohort, we believe this negative result was due to the early demise of these mice precluding formation of overt mammary neoplasms. Although we did see evidence of mammary hyperplasia in aged (9-12 months) Rb þ /À mice, this was complicated by the frequent observation of galactorrhea, evidence of excessive prolactin secretion (both a mammary mitogen and an activator of b-lactoglobulin expression; and therefore the transgene), in each of these genotypes. Indeed, we observed extensive transgene expression in the mammary alveolar epithelia of these mice. This gives an indication that even in the presence of combined deregulated cyclin E expression and a mammary mitogen, tumor latency is likely to be considerable.
Altered cyclin E expression has been reported in lesions arising from a great many tissues including the skin, mesothelium, oral cavity, lung, breast, uterus, ovary, stomach, intestine, colon, gall bladder, pancreas, kidney, urinary bladder, testis, thyroid, adrenal gland, lymphoid and myeloid lineages, nervous system, smooth muscle, fat and skeletal muscle. In each tumor type alterations are reported at frequencies ranging from 2 to 40%. Loss of p53 function is a common finding in tumors arising in most tissues with frequencies up to 80% in some tumor types and thus overlap with cyclin E deregulation is inevitable. However, to date, there are few studies correlating p53 status with cyclin E deregulation in individual tumors.
What cellular/genomic events could lead to deregulated cyclin E rather than overexpression? Normally, cyclin E is regulated at the level of transcription and at the level of protein stability. When a fraction of the Cdk2 complex is active, cyclin E is phosphorylated on residues T62 and/or T380 (Clurman et al., 1996; Won and Reed, 1996; Strohmaier et al., 2001) , among other probable sites (Welcker et al., 2003) , targeting it for ubiquitination by SCF hCdc4/Fbw7 and subsequent degradation by the 26S proteasome. Although phosphorylation site mutations have not been reported in tumors, mutations in hCdc4/Fbw7 have been found in breast, ovarian, pancreatic, colorectal and endometrial carcinomas (Moberg et al., 2001; Spruck et al., 2002; Calhoun et al., 2003; Rajagopalan et al., 2004) and lymphomas (Qiu et al., 2003) . Interestingly, endometrial (Ekholm-Reed et al., 2004b) , pancreatic (Calhoun et al., 2003) and colorectal carcinomas (Rajagopalan et al., 2004) with hCdc4/Fbw7 mutations show loss of cyclin E cell cycle regulation, which is likely to be equivalent to constitutive expression of a less-degradable allele as with the model presented here. These tumors have also been shown to exhibit high levels of aneuploidy (Hubalek et al., 2004) , consistent with the hypothesis that deregulation of cyclin E relative to the cell cycle causes genomic instability leading to carcinogenesis. In a recent study, similar to ours in concept, p53
þ /À MMTV-cyclin D1 mice did not develop mammary tumorigenesis (Hosokawa et al., 2001 ) above the penetrance induced by MMTV-cyclin D1 alone (Wang et al., 1994) . This is suggestive of a distinct mechanism and is consistent with our previous observation that deregulation of cyclin D1 does not induce chromosome instability in cultured cells (Spruck et al., 1999) .
In summary, we present evidence that in vivo deregulated cyclin E in the mammary gland of the mouse induces tumorigenesis by inducing genomic instability. Loss of p53 appears to be a key early event in this model and deregulation of cyclin E and inactivation of p53 show synergy in tumorigenesis. Recent description of a novel tumor suppressor, hCdc4, the loss of which directly leads to deregulated expression of cyclin E provides one upstream mechanism by which deregulation may occur in spontaneous lesions.
Materials and methods

Mice
CycE and T380A transgenic mice were generated by integration of the human cyclin E sequence under the control of the ovine b-lactoglobulin promoter in a pBJ41 plasmid as previously described (Bortner and Rosenberg, 1997) . Both lines were generated in a C3H Â C57BL/6J mixed background, backcrossed to BL/6 parent and subsequently by brother Â sister crosses. p53 þ /À mice in C57BL/6J background were purchased and bred under agreement with Taconic Farms. Transgenic/KO lines were generated by crossing a transgenic homozygous male with a heterozygous p53 þ /À female. Female F1 progeny heterozygous at both the transgene insertion locus and tumor suppressor locus were backcrossed to the transgenic male parent to generate F2 progeny homozygous at the transgene insertion locus and heterozygous at the tumor suppressor locus. Once established, each line was maintained by F2 þ /À Â þ / þ brother Â sister crosses. Thus 50% of the female progeny were heterozygous at the TRP53 locus and 50% were wild-type controls. Control mice, heterozygous at the TRP53 locus but transgene negative, were generated from F1 crosses and maintained similarly by F2 crosses. In this manner all mice were generated in an equivalent C3H/C57BL/ 6J Â C57BL/6J genetic background. TSRI has maintained AAALAC accreditation since February 1986.
Genotyping was performed at weaning by polymerase chain reaction (PCR) on genomic DNA extracted from tail clips and retrospectively at necropsy for confirmation. Transgene zygosity (data not shown) was determined by a combination of analysis of inheritance and semiquantitative PCR analysis using Cks1 primers as an internal control .
In order to detect a twofold increase in tumor penetrance we determined ex ante that 32 mice were required for each genotype. Therefore, a minimum of 50 females from each genotype were bred, put through two pregnancies and aged to cover losses through the exclusion criteria below. All mice evaluated in the study were set up in breeder cages for two pregnancies to induce the transgene (or comparable parity in non-transgenic mice). Transgenic mice were included only if homozygous at the transgene locus. Mice were excluded from analysis of tumor penetrance if they met one of the following criteria; (i) o2 pregnancies, (ii) premature killing or death from non-neoplastic lesions, (iii) premature death or killing before the appearance of the first mammary lesion observed in any of the genotypes. Only female mice were studied. After two pregnancies (used to activate the cyclin E transgene in the mammary epithelia) each mouse was aged to 18 months based upon published life expectancies for p53 þ /À mice. Each mouse underwent a full necropsy which included, but was not limited to, routine histological examination of the mammary glands. Histological examination of likely sites of tumor metastases were also routinely made, typically lung, liver and bone marrow. Tissues were fixed in 10% neutral buffered formalin for 24 h, embedded in paraffin, sectioned to 3 mm and stained with hematoxylin and eosin by standard methods.
Immunohistochemistry and immunocytochemistry
Unstained paraffin-embedded sections were deparaffinized and rehydrated by xylene and graded alcohol series by standard methods. Antigen retrieval was achieved by microwave in Vector Labs antigen retrieval solution or Retrievagen A (pH 6.0; BD Pharmingen, San Diego, CA, USA) for cyclin B1. Endogenous peroxide activity was blocked with 5 min incubation in 3% hydrogen peroxide in water. Sections were washed in buffer and standard immunohistochemistry was performed using Vector Labs Vectorstain s ABC elite and Vector s Mouseon-Mouset immunodetection kits. Primary antibodies used were; for human transgenes cyclin E and T380A (HE12 monoclonal mouse anti-human cyclin E imunoglobulin (IgG) 1:500); mouse cyclin E, M20 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) polyclonal rabbit anti-mouse/human cyclin E (1:100); PC10 (Santa Cruz Biotechnology) monoclonal antiproliferating cell nuclear antigen (PCNA) (1:1000) and GNS-1 (BD Pharmingen) monoclonal anti-cyclinB1 (1:100). Immunoperoxidase activity was detected by 3,3 0 -diaminobenzidine (DAB) or AEC substrates and sections were counterstained with hematoxylin briefly (1-2 s) for contrast. For quantitative immunocytochemistry, images were taken using a Deltavision deconvolution microscope and the average pixel intensity was measured for individual cells using Image Jsoftware.
Cells growing on polylysine-coated coverslips were washed once with phosphate-buffered saline (PBS) and then fixed in 1% paraformaldehyde for 10 min. After the paraformaldehyde was aspirated, the cells were incubated in methanol (À201C) for a further 10 min, washed for 15 min in 0.1% Triton-X100 in PBS (TPBS) at room temperature then finally immersed in PBS (41C) until analysis. For analysis, coverslips were blocked in 1% BSA in TPBS for 30 min at 371C. Primary antibodies were added overnight at 41C. Following two washes in TPBS, secondary antibody/fluorochrome conjugates (Donkey antiRabbit/Rhodamine and Goat anti-mouse/Cy2) were added for 30 min at 371C. Cells were washed twice in TBPS, dehydrated through a graded alcohol series, air-dried and mounted with DAPI for nuclear staining. Antibodies used for immunocytochemistry were the mitosis marker (Upstate Biotechnology Inc., Lake Placid, NY, USA) rabbit polyclonal anti-phosphohistone 3 (Serine 10; 1:500) and GNS-1 (BD Pharmingen) mouse monoclonal anti-human cyclin B1 (1:400).
Tumor cell culture and tissue harvest Mice bearing tumors of suspected mammary origin were killed by inhalation overdose of halothane (>5%) by open drop technique. At necropsy, mammary lesions were excised under aseptic conditions complete with any involved tissue attached. A portion roughly equal to half the lesion including any involved adjacent tissues and the overlying integument was taken to fix in 10% neutral-buffered formalin for histological examination. The remaining portion was cleaned of adherent tissues and divided into parts for protein/genomic DNA analysis (frozen À801C until analysis) and culture. The latter was finely diced and part was seeded directly into one well of a collagen IV coated six-well tissue culture plate and the other part was digested for 1-2 h in collagenase type III and centrifuged through a density gradient before seeding onto another well of the collagen IV coated six-well tissue culture plate. Cultures were maintained in serum-free complete mouse mammary medium (CMMM) composed of Dulbecco's modified Eagle medium (DMEM):F12 medium (1:1) supplemented with HEPES 50 mM, 5 mg/ml BSA fraction V, 10 ng/ml EGF, 10 mg/ml insulin, 10 mg/ml transferin, 10 ng/ml Choleratoxin, penicillin and streptomycin. For longer-term storage of cultures, the cells were frozen in liquid nitrogen in CMMM: adult male horse serum (1:1) supplemented with 10% dimethylsulphoxide (DMSO). Fetal calf serum (FCS) was avoided because of probable prolactin content.
Mouse embryonic fibroblasts (MEFs) were cultured in DMEM supplemented with 10% FCS by standard methods. Third passage MEFs were seeded into two 6-cm culture dishes and infected overnight with medium containing the empty pBabeHygro retrovirus vector or pBabeHygro retrovirus containing E6. The following day both cultures were passaged and seeded into 10-cm dishes and reinfected overnight. On day 3, the cells were again passaged and each culture was seeded into two 10-cm dishes and reinfected overnight. On day 4, the cells passaged for a fourth time seeding into dishes or onto coverslips at 50% confluence. The final day cells from the dishes were harvested and prossessed for western analysis by 7.5% SDS-polyacrylamide gel electrophoresis. Cells growing on polylysine-coated coverslips were processed from immunocytochemistry as described above.
Immunoblotting
Western analysis was performed by standard techniques. Briefly, tissues frozen at necropsy (À801C) were weighed, diced with a scalpel or razor blade, suspended in lysing matrix (Q-BIOgene) and lysed using a FastPrep FP120 Cell Disrupter in NP-40 lysis buffer; 0.5% NP40 (v/v), 50 mM Tris pH 8.0, 700 mM NaCl, 20 mM NaF, 20 mM b-glycerophosphate, 0.1 mM Na 3 VO 4 , 1 mM dithiothreitol (DTT), 10 mg/ml Leupeptin, 10 mg/ml Aprotinin, 0.2% Pefabloc (v/v). Phenylmethylsulphanyl fluoride was added to a final concentration of 1 mg/ml and the samples were incubated on ice for 30 min. The non-lipid soluble fraction was collected after centrifugation at 10 000 g for 10 min. Cells were lysed by the direct addition of lysis buffer to the dish or after trypsin passage from flasks. After separation by polyacrylamide SDS gels, proteins were transferred semi-dry to Immobilont polyvinylidene difluoride (PVDF) membranes. Antibodies used for western analysis were HE12 monoclonal anti-human cyclin E (1:1000), C19 (Santa Cruz Biotechnology) polyclonal anti mouse cyclin A (1 mg/ ml), GNS-1 (BD Pharmingen) monoclonal anti-cyclinB1 (1:500), ab8227 (Abcam) polyclonal rabbit anti-human b-actin (1:5000) loading control. Detection of horseradish peroxidase (HRP)-conjugated secondary antibodies was performed using chemiluminescence (Pierce Biotechnology Inc., Rockford, IL, USA).
Loss of heterozygosity analysis
Loss of heterozygosity was determined by Southern analysis and multiplex PCR. In the few cases where tumors were cystic or had large areas of necrosis material was limiting (i.e. o10 mg DNA available) and only multiplex PCRs were performed. Tumor DNA was extracted by proteinase K digestion followed by phenol/chloroform purification by standard methods also used for tail genomic analysis. For Southern analysis, 10 mg of genomic DNA was digested with Bam H1 transferred to Zeta-probe s nylon membranes and probed with DNA probes corresponding to a 32 P-labeled 256-bp fragment of Exon IV, a 381-bp fragment of Exon XI (both common to wild-type allele, mutant allele and pseudogene) or the 106-bp deletion of Exon V (Donehower et al., 1992) . For multiplex PCR, 100 ng of genomic DNA was used in each PCR reaction. Each set of multiplex reactions were prepared from 'master mixes' deficient only for the target DNA. As the only difference between the wild-type and mutant p53 alleles was a small 106-bp deletion of exon V and B1.5 kbp Pol II/Neo cassette insertion (Donehower et al., 1992) , multiplex PCR of the wild-type allele was designed across or from within the deletion. Under these conditions, the ratio of p53 wild-type/ null allele in control reactions were comparable over a range of 10-1000 ng/reaction (i.e. 10 fold less to 10 fold more than used for LOH analysis). For Southern analysis of p53 þ /À mice LOH was assigned to a tumor when >50% of the wild-type signal was lost when compared to the mutant allele (or to the pseudogene for T380A wild-type for p53) for which an approximate 1N DNA content was assumed. Loss of heterozygosity was also assigned when the wild-type p53 allele/ internal control signal ratio was o50% of the control p53 þ /À DNA in at least three independent p53 multiplex reactions (i.e. with three different sets of control primers). Genomic amplification of more than three of the genes used as control sequences was deemed improbable. Internal control sequences included the p53 mutant allele, p53 pseudogene, and the loci of Cks1 and Rb.
Statistical analysis
Analysis of survival was performed using the log-rank test. Analysis of tumor penetrance was performed using w 2 and Fischer's exact tests. Latency was assessed using ANOVA. For each test, Po0.05 was considered statistically significant.
